Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology
- PMID: 22169944
- PMCID: PMC3280652
- DOI: 10.1038/npp.2011.285
Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology
Abstract
Individual characteristics of pathophysiology and course of depressive episodes are at present not considered in diagnostics. There are no biological markers available that can assist in categorizing subtypes of depression and detecting molecular variances related to disease-causing mechanisms between depressed patients. Identification of such differences is important to create patient subgroups, which will benefit from medications that specifically target the pathophysiology underlying their clinical condition. To detect characteristic biological markers for major depression, we analyzed the cerebrospinal fluid (CSF) proteome of depressed vs control persons, using two-dimensional polyacrylamide gel electrophoresis and time-of-flight (TOF) mass spectrometry peptide profiling. Proteins of interest were identified by matrix-assisted laser desorption ionization TOF mass spectrometry (MALDI-TOF-MS). Validation of protein markers was performed by immunoblotting. We found 11 proteins and 144 peptide features that differed significantly between CSF from depressed patients and controls. In addition, we detected differences in the phosphorylation pattern of several CSF proteins. A subset of the differentially expressed proteins implicated in brain metabolism or central nervous system disease was validated by immunoblotting. The identified proteins are involved in neuroprotection and neuronal development, sleep regulation, and amyloid plaque deposition in the aging brain. This is one of the first hypothesis-free studies that identify characteristic protein expression differences in CSF of depressed patients. Proteomic approaches represent a powerful tool for the identification of disease markers for subgroups of patients with major depression.
Figures








Similar articles
-
Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.Neurol Res. 2006 Mar;28(2):155-63. doi: 10.1179/016164106X98035. Neurol Res. 2006. PMID: 16551433
-
Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients.J Affect Disord. 2018 May;232:134-138. doi: 10.1016/j.jad.2018.02.039. Epub 2018 Feb 21. J Affect Disord. 2018. PMID: 29486339
-
Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization--mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry.Electrophoresis. 2000 Jun;21(11):2266-83. doi: 10.1002/1522-2683(20000601)21:11<2266::AID-ELPS2266>3.0.CO;2-Z. Electrophoresis. 2000. PMID: 10892737
-
Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies.Expert Rev Proteomics. 2017 Jun;14(6):499-514. doi: 10.1080/14789450.2017.1336435. Expert Rev Proteomics. 2017. PMID: 28562112 Review.
-
Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.J Mass Spectrom. 2008 May;43(5):559-71. doi: 10.1002/jms.1409. J Mass Spectrom. 2008. PMID: 18416436 Review.
Cited by
-
Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis.J Transl Med. 2021 Jan 15;19(1):34. doi: 10.1186/s12967-021-02702-y. J Transl Med. 2021. PMID: 33451315 Free PMC article.
-
Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats.Pharmaceuticals (Basel). 2022 Aug 26;15(9):1063. doi: 10.3390/ph15091063. Pharmaceuticals (Basel). 2022. PMID: 36145284 Free PMC article.
-
Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses.Psychiatry Investig. 2015 Apr;12(2):249-59. doi: 10.4306/pi.2015.12.2.249. Epub 2015 Mar 18. Psychiatry Investig. 2015. PMID: 25866527 Free PMC article.
-
High mobility group box 1 and a network of other biomolecules influence fatigue in patients with Crohn's disease.Mol Med. 2023 Jun 26;29(1):81. doi: 10.1186/s10020-023-00679-6. Mol Med. 2023. PMID: 37365509 Free PMC article.
-
The promise of biomarkers in diagnosing major depression in primary care: the present and future.Curr Psychiatry Rep. 2015 Aug;17(8):601. doi: 10.1007/s11920-015-0601-1. Curr Psychiatry Rep. 2015. PMID: 26081681 Review.
References
-
- Brummer D, Evans D, Berg D, Greten H, Beisiegel U, Mann WA. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia. J Mol Med. 1998;76:355–364. - PubMed
-
- Brunner J, Bronisch T, Uhr M, Ising M, Binder E, Holsboer F, et al. Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur Arch Psychiatry Clin Neurosci. 2005;255:438–440. - PubMed
-
- Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord. 2004;79:285–289. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources